全文获取类型
收费全文 | 11202篇 |
免费 | 773篇 |
国内免费 | 79篇 |
专业分类
耳鼻咽喉 | 98篇 |
儿科学 | 166篇 |
妇产科学 | 144篇 |
基础医学 | 1770篇 |
口腔科学 | 210篇 |
临床医学 | 1029篇 |
内科学 | 2430篇 |
皮肤病学 | 188篇 |
神经病学 | 1098篇 |
特种医学 | 446篇 |
外科学 | 1698篇 |
综合类 | 131篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 641篇 |
眼科学 | 317篇 |
药学 | 858篇 |
中国医学 | 25篇 |
肿瘤学 | 799篇 |
出版年
2023年 | 81篇 |
2022年 | 274篇 |
2021年 | 459篇 |
2020年 | 226篇 |
2019年 | 249篇 |
2018年 | 352篇 |
2017年 | 228篇 |
2016年 | 277篇 |
2015年 | 353篇 |
2014年 | 435篇 |
2013年 | 546篇 |
2012年 | 816篇 |
2011年 | 908篇 |
2010年 | 474篇 |
2009年 | 451篇 |
2008年 | 710篇 |
2007年 | 697篇 |
2006年 | 649篇 |
2005年 | 653篇 |
2004年 | 564篇 |
2003年 | 532篇 |
2002年 | 489篇 |
2001年 | 83篇 |
2000年 | 61篇 |
1999年 | 80篇 |
1998年 | 98篇 |
1997年 | 89篇 |
1996年 | 62篇 |
1995年 | 61篇 |
1994年 | 66篇 |
1993年 | 55篇 |
1992年 | 45篇 |
1991年 | 50篇 |
1990年 | 47篇 |
1989年 | 43篇 |
1988年 | 44篇 |
1987年 | 30篇 |
1986年 | 35篇 |
1985年 | 28篇 |
1984年 | 36篇 |
1983年 | 38篇 |
1982年 | 48篇 |
1981年 | 45篇 |
1980年 | 50篇 |
1979年 | 37篇 |
1978年 | 33篇 |
1977年 | 33篇 |
1976年 | 32篇 |
1975年 | 27篇 |
1974年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
Flavio Roberto Takeda Marcus Fernando Kodama Pertille Ramos Marina Alessandra Pereira Renan Rosetti Muniz Francisco Tustumi Tiago Biachi de Castria Rubens Antonio Aissar Sallum Bruno Zilberstein Ulysses Ribeiro Junior Ivan Cecconello 《American journal of surgery》2021,221(3):631-636
IntroductionAdenocarcinoma of the esophagogastric junction (AEGJ) represents a poor prognostic tumor. We evaluated the recurrence pattern and risk factors associated with recurrence in patients undergoing surgical resection by AEJG.MethodsRecurrences were categorized as locoregional, peritoneal, or distant. These three recurrence groups and a non-recurrence group were compared, and overall survival (OS) and disease-free survival (DFS) for each one was obtained.ResultsWe analyzed 188 patients with curative surgical treatment. Recurrence was observed in 72 (38.3%) patients. Locoregional recurrence was observed in 17 (23.6%); 20 (27.8%) peritoneal recurrence and 35 (48.6%) distant metastasis. DFS was 9, 5, and 8 months, and OS was 21.8, 13.2, and 20.8, respectively. Tumors larger than 5 cm are risk factors for peritoneal recurrence (OR:2.88, p = 0.012). Positive lymph nodes were related to distant metastasis (OR:9.15, p = 0.040), and lymphatic invasion for locoregional recurrence (OR:3.81, p = 0.028).ConclusionAEGJ is associated with high rates of early recurrence. 相似文献
72.
Shamsah Kazani David J. Rowlands Ivan Bottoli Julie Milojevic Jose Alcantara Ieuan Jones Kenneth Kulmatycki Surendra Machineni Lidia Mostovy Ian Nicholls Jerry A. Nick Steven M. Rowe Nicholas J. Simmonds Raju Vegesna Jeroen Verheijen Henry Danahay Martin Gosling Phaninatha Sarma Ayalavajjala Robert Strieter 《Journal of cystic fibrosis》2021,20(2):250-256
BackgroundThis is the first-in-human study of icenticaftor, an oral potentiator of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) channel. Restoration of CFTR activity has shown significant clinical benefits, but more studies are needed to address all CFTR mutations.MethodsSafety, pharmacodynamics/pharmacokinetics of icenticaftor were evaluated in a randomized, double-blind, placebo-controlled study in healthy volunteers. Efficacy was assessed in adult CF patients with ≥1 pre-specified CFTR Class III or IV mutation (150 and 450 mg bid), or homozygous for F508del mutation (450 mg bid). Primary efficacy endpoint was change from baseline in lung clearance index (LCI2.5). Secondary endpoints included %predicted FEV1 and sweat chloride level.ResultsClass IV mutations were present in 22 patients, Class III in 2 (both S549N), and 25 were homozygous for F508del. Icenticaftor was well-tolerated in healthy and CF subjects with no unexpected events or discontinuations in the CF groups. The most frequent study-drug related adverse events in CF patients were nausea (12.2%), headache (10.2%), and fatigue (6.1%). Icenticaftor 450 mg bid for 14 days showed significant improvements in all endpoints versus placebo in patients with Class III and IV mutations; mean %predicted FEV1 increased by 6.46%, LCI2.5 decreased by 1.13 points and sweat chloride decreased by 8.36 mmol/L. No significant efficacy was observed in patients homozygous for a single F508del.ConclusionsIcenticaftor was safe and well-tolerated in healthy volunteers and CF patients, and demonstrated clinically meaningful changes in lung function and sweat chloride level in CF patients with Class III and IV CFTR mutations.ClinicalTrials.gov: NCT02190604 相似文献
73.
74.
Kutner Bryan A. Simoni Jane M. Aunon Frances M. Creegan Emma Balán Ivan C. 《Archives of sexual behavior》2021,50(4):1651-1663
Archives of Sexual Behavior - Gay, bisexual, and other men who have sex with men (MSM) experience alarming HIV disparities alongside sub-optimal engagement in HIV interventions. Among MSM, stigma... 相似文献
75.
76.
Matja Popit Lijana Zaletel-Kragelj Ivan Eren Lorna Zadravec-Zaletel Marjan Zaletel 《Slovenian Journal of Public Health》2021,60(1):38
AimWith the aim of providing a foundation for evidence-based public health actions, as well as the more individualised clinical treatment of migraine in Slovenia, the objective of our study was to assess the association between poor self-rated health (PSRH) and migraine, adjusted for selected comorbidity and socioeconomic factors.MethodsThe survey, conducted between August and December 2014, involved included 6,262 adults aged 15 years and over. Binary logistic regression was used in univariate as well as multivariate analysis. Three multivariate models were defined: MODEL 1 (migraine and comorbidities related to the physical dimension of health); MODEL 2 (comorbidities related to the mental dimension of health); MODEL 3 (demographic and socioeconomic factors).ResultsIn univariate as well as all three multivariate models, the odds of PSRH were statistically significantly higher in migraine sufferers in comparison to non-sufferers (univariate model: ORmigraine=yes vs. migraine=no=2.22 (p<0.001); MODEL 1: ORmigraine=yes vs. migraine=no=2.27 (p<0.001); MODEL 2: ORmigraine=yes vs. migraine=no=1.51 (p=0.002); MODEL 3: ORmigraine=yes vs. migraine=no=1.56 (p=0.001)).ConclusionMigraine is an important PSRH-related factor. Comorbidities related to the physical dimension of health do not reduce the power of association between migraine and PRSH, while comorbidities related to the mental dimension reduce the power of association of migraine and other health conditions. The power of the association between migraine and PRSH is also independent of demographic/socioeconomic factors. We can also conclude that migraine seems to be a phenomenon that is in a bi-directional relationship with mental states (thus having an impact on PSRH) and is itself a stressor. 相似文献
77.
Anselm Frick Ivan Durasin Mechtild Neuweg 《Pflügers Archiv : European journal of physiology》1986,406(4):387-391
Clearance experiments have been performed to study the effects of saline infusion on the reabsorption of inorganic sulfate (SO4) at endogenous levels. Adult female Sprague-Dawley rats on a standard diet were used. Both intact and thyroparathyroidectomized (TPTX) animals were infused with a 130 mmol/l sodium chloride solution at a low (0.15 ml/min) and a high (0.375 ml/min) rate. This increase of the infusion rate decreased the reabsorption of SO4 in both groups of animals significantly. The fractional excretion of SO4 in theintact rats increased from 9.9±5.6 to 18.4±3.6% (mean values±SD,p<0.001) and in theTPTX rats from 5.3±2.5 to 22.4±6.3% (p<0.001). It is concluded that endogenous parathyroid hormone has no major effect on the saline-induced inhibition of reabsorption of SO4.This work was supported by a grant from the Deutsche Forschungsgemeinschaft (Fr 239/9-1) 相似文献
78.
Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus 总被引:13,自引:0,他引:13
Li H Zhang L Lou H Ding I Kim S Wang L Huang J Di Sant'Agnese PA Lei JY 《American journal of clinical pathology》2005,124(2):282-287
Overexpression of decoy receptor (DcR) 3 protein, a recently discovered member of the tumor necrosis factor receptor superfamily, was examined in 40 esophagogastrectomy specimens containing areas of Barrett esophagus (n = 27), low-grade dysplasia (n = 27), high-grade dysplasia or carcinoma in situ (n = 22), and esophageal adenocarcinoma (EAC; n = 28) with immunohistochemical analysis. The results revealed significantly more overexpression of DcR3 in high-grade dysplasia or carcinoma in situ and EAC than in benign esophageal mucosa (both P < .0001), Barrett esophagus (both P < .001), and low-grade dysplasia (P < .01 and P = .033, respectively). Low-grade dysplasia also showed significant overexpression of DcR3 compared with benign esophagus (P < .05) but not with Barrett esophagus (P > .05). DcR3 overexpression seems to negatively correlate with the grade of EAC. Our results suggest that overexpression of DcR3 protein might aid in the diagnosis of high-grade dysplasia or carcinoma in situ and EAC and also might serve as a potential therapeutic target. 相似文献
79.
Gian Marco Moneta Claudia Bracaglia Ivan Caiello Chiara Farroni Denise Pires Marafon Raffella Carlomagno Linda Hiraki Marina Vivarelli Alessandra Gianviti Simone Carbogno Walter Ferlin Cristina de Min Earl Silverman Rita Carsetti Fabrizio De Benedetti Emiliano Marasco 《European journal of immunology》2023,53(7):2250319
80.
Ziggi Ivan Santini Lau Caspar Thygesen Steinar Krokstad Lars Ole Bonde Robert J. Donovan Vibeke Koushede Anita Jensen Ai Koyanagi Ola Ekholm 《British journal of health psychology》2023,28(3):844-859